BiotechTube

Lotilaner Gel, 2.0%

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papulopustular Rosacea

Conditions

Papulopustular Rosacea

Trial Timeline

Mar 1, 2023 → Nov 13, 2023

NCT ID
NCT05838170

About Lotilaner Gel, 2.0%

Lotilaner Gel, 2.0% is a phase 2 stage product being developed by Tarsus Pharmaceuticals for Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT05838170. Target conditions include Papulopustular Rosacea.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05838170Phase 2Completed

Competing Products

18 competing products in Papulopustular Rosacea

See all competitors
ProductCompanyStageHype Score
Deucravacitinib + PlaceboBristol Myers SquibbPhase 2
51
Topical Dapsone 5% Gel + oral antibioticsBristol Myers SquibbPhase 3
76
Azelaic acid (Finacea, BAY39-6251) + Metronidazole (Metrogel) + Doxycycline (Oracea)BayerApproved
82
Azelaic Acid foam 15%BayerApproved
82
Azelaic acid + Vehicle foamBayerPhase 2
49
Azelaic acid foam 15% + Vehicle foamBayerPhase 2
49
azelaic acid 15% gel + azelaic acid 15% gelBayerApproved
82
Azelaic Acid Foam + Azelaic Acid GelBayerPhase 1
30
Azelaic acid foam, 15% (BAY39-6251) + Vehicle foamBayerPhase 3
74
DFD-29 + Doxycycline + PlaceboDr. Reddy's LaboratoriesPhase 3
74
DFD-29 + Doxycycline + PlaceboDr. Reddy's LaboratoriesPhase 3
74
Encapsulated Benzoyl Peroxide CreamSol-Gel TechnologiesPhase 1
25
S5G4T-1Sol-Gel TechnologiesPhase 3
69
S5G4T-1 + S5G4T-2Sol-Gel TechnologiesPhase 3
69
S5G4T-1 + S5G4T-2Sol-Gel TechnologiesPhase 3
69
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
69
FMX103 1.5%Vyne TherapeuticsPhase 3
69
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
69

Other Products from Tarsus Pharmaceuticals

Lotilaner ophthalmic solution, 0.25% + Vehicle controlApproved
80
TP-03 + TP-03 VehiclePhase 3
72
TP-03, 0.25% + TP-03 VehiclePhase 2/3
60
Vehicle of TP-03Phase 2
47
lotilaner + VehiclePhase 2
47